Search Results - "Brusquant, D."

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., Taieb, J., Brucker, P., Landi, B., Flesch, M., Carola, E., Martin, P., Vaillant, E., de Gramont, A.

“…The sequential FOLFOX7–FOLFIRI combination is not superior to FOLFOX4 in colorectal cancer patients with resectable metastases. Patients with synchronous…”
Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., de Gramont, A.

Get full text

Impact of age on treatment efficacy and safety in metastatic colorectal cancer: A subgroup analysis from the GERCOR Dream phase III study by Bengrine-Lefevre, L, Chibaudel, B, Tournigand, C, Carola, E, Brusquant, D, de Gramont, A

Get full text

Two new cases of the Christchurch (Ch1) chromosome 21: evidence for clinical consequences of de novo deletion 21P by Vorsanova, S G, Yurov, Yu B, Brusquant, D, Carles, E, Roizes, G

“…We performed an investigation of two unrelated cases with extremal variants of chromosome 21 without visible materials of the short arms (Christchurch or Ch1…”
Get more information